Normativa de profilaxis de la enfermedad tromboembólica venosa

Archivos de Bronconeumologia

Volumn 32, Issue 7, 1996, Pages 348-355

  Ruiz Manzano, J ^a   Alberich, P ^b   Blanquer, J ^b   Capelastegui, A ^b   Cabezudo, M A ^b   De Gregorio, M A ^b   Rodriguez F ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BOXOL; DALTEPARIN; DECIPAR; ENOXAPARIN; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; UNCLASSIFIED DRUG;

HUMAN; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POSTOPERATIVE COMPLICATIONS; PRESSURE; PULMONARY VEINS; RISK FACTORS; THROMBOSIS;

EID: 0005644209     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-2896(15)30740-7     Document Type: Article

References (60)

1. Turpie AG, Leclerc JR. Prophylaxis of venous thromboembolism. En: Leclerc JR, editor. Venous thromboembolic disorders. Filadelfia. Lea & Febiger, 1991; 303-345.
2. Consensus Conference Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-749.
3. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1989; 95 (Supl): 37-55.
4. Hirsh J, Levine M, Turpie AG. Prévention de la maladie thrombo-embolique. En: Simmoneau G, Huet Y, editores. Embolie pulmonaire et thrombose veineuse profonde. París: Masson, 1990; 167-183.
5. Roskob GE, Hull RD. Practical approach for preventing venous thromboembolism. En: Kwann HC, Samama MM, editores. Clinical thrombosis. Miami: CRC Press, 1989; 91-106.
6. Gallus AS. Anticoagulants in the prevention of venous thromboembolism. En: Hirsch J, editores. Antithrombotic therapy. Baillière's Clinical Haematology 1990; 3: 651-684.
7. Hirsh J, Hull RD. A practical approach to the profilaxis of venous thromboembolism. En: Venous thromboembolism: natural history, diagnosis and management. Boca Raton, Florida: CRC Pres. 1987; 117-129.
8. Clagett GP, Resich JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227-240.
9. Clagett GP, Anderson FA, Levine MK, Salzaman EW, Wheeler HB. Prevention of venous thromboembolism. Chest 1992; 102 (Supl): 391-407.
10. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopaedic, and urologie surgery. N Engl J Med 1988; 318: 1.162-1.173.
11. Thromboembolic Risk Factors Consensus Group. Risk of and profilaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
12. Morgenthaler TI, Ryu JH. Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc 1995; 70: 417-424.
13. Rasmussen MS, Wille-Jorgensen P, Jorgensen LN. Postoperative fatal pulmonary embolism in a general surgical department.
14. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1.660-1.664.
15. Monreal M, Ruiz J, Olazábal A, Arias A, Roca J. Deep venous thrombosis and the risk of pulmonary embolism. A systematic study. Chest 1992; 102: 677-681.
16. Anderson FA, Wheeler HB. Venous thromboembolism. Risk factors and prophylaxis. Clin Chest Med 1995; 16: 235-251.
17. Cogo A, Bernardi E, Prandoni P, Girolami B, Noventa F, Simioni P et al. Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-168.
18. Monreal M, Raventós A, Lerma R, Ruiz J, Lafoz E, Alatrué A et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: a prospective study. Thromb Haemost 1994; 72: 548-550.
19. Nachman RL, Silverstein R. Hypercoagulable state. Ann Intern Med 1993; 199: 819-823.
20. Wells PS, Lensing AWA, Hirsch J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. A metaanalysis. Arch Intern Med 1994; 154: 67-72.
21. Hirsh J. Heparin. N Engl J Med 1991; 324: 1.565-1.574.
22. Hirsh J, Dalen JE, Deykin D, Poller L. Heparine: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy an safety. Chest 1992; 102 (Supl): 337-351.
23. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight-heparin or unfractioned heparin. N Engl J Med 1995; 332: 1.330-1.335.
24. Taberner DA, Poller L, Thompson JM, Lemon G, Weighill FJ. Randomized study of adjusted versus fixed low dose heparing prophylaxis of deep vein thrombosis in hip surgery. Br J Surg 1989; 76: 933-935.
25. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
26. Fareed J, Walenga J, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Sem Thromb Haemost 1989; 15: 440-463.
27. Levine MN, Hirsh J. Clinical potential of low molecular weight heparins. Baillière's Clinical Haematology 1990; 3: 545-553.
28. Coccheri S. Low molecular weight heparins: an introduction. Haemostasis 1990; 20(Supl 1): 74-80.
29. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995; 155: 366-372.
30. Bergqvist D, Burmark US, Frisell J, Hallböök T, Lindblad B, Risberg B et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208.
31. Bergqvist D, Mätzsch T, Burmark US, Frisell J, Guilbaud O, Hallböök T et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988; 75: 888-891.
32. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ et al. A randomized controlled trial of a low-molecular-weight heparin (enoxiparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929.
33. Haas S, Blümel G. Prophylaxis of thromboembolism with various low-molecular-weight heparins. Haemostasis 1988; 18: (Supl 3): 82-87.
34. Pezzuoli G, Neri GG, Settembrini PG, Coggi G, Olivari N, Buzetti G et al. Effectiveness and safety of the low-molecular-weigth heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. Haemostasis 1990; 20 (Supl 1): 193-204.
35. Kakkar VV, Djazaeri B, Fok J, Fletcher M. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. BMJ 1982; 284: 375-379.
36. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-920.
37. Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vanderbroucke JP. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a metaanalysis. Lancet 1992; 340: 152-156.
38. Haas S, Haas P. Efficacy of low molecular weight heparins: an overview. Semin Thromb Haemost 1993; 19 (Supl 1): 101-106.
39. Bergqvist D. Perioperative hemorrhagic complications in patients on low molecular weight heparins. Semin Thromb Hemost 1993; 19 (Supl 1): 128-130.
40. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2.500 versus 5.000 XaI units in 2.070 patients. Br J Surg 1995; 82: 496-501.
41. Haas S, Flosbach CW. Prevention of postoperative thromboembolism with enoxaparin in general surgery: a german multicenter trial. Semin Thromb Hemost 1993; 19 (Supl 1): 164-173.
42. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265.
43. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T et al. A comparison of subcutaneous low-molecular-weight heparing with warfarin sodium for thromboembolism against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1.370-1.376.
44. Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423-428.
45. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgial and medical patients. BMJ 1994; 308; 235-246.
46. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs. The relationship between dose, effectiveness and side effects. Chest 1992; 102 (Supl): 327-336.
47. Eriksson BI, Kälebo P, Ekman S, Kerry R, Baur M, Bach D et al. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin, CGP 39393 (Revasc), Ciba, compared to unfractioned heparin. Circulation 1994; 90: 3.066.
48. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704.
49. Ziomek S, Read RC, Tobler G, Harrell JE, Gocio JC, Fink LM et al. Throembolism in patients undergoing thoracotomy. Ann Thorac Surg 1993; 56: 223-227.
50. Mohr DN, Silverstein MD, Murtaugh PA, Harrisob JM. Prophylactic agents using venographic assessment. Arch Intern Med 1993; 153: 2.221-2.228.
51. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparing and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1.742-1.746.
52. Leclerc JR, Geerts W. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low-molecular-weight heparin (enoxaparin) to placebo. Thromb Haemost 1992; 67: 417-423.
53. Bergqvist D, Bergentz SE, Bornmyr S, Husberg B, Konrad P, Lungner H et al. Deep-vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res 1985; 17: 69-74.
54. Ginsberg JS, Hirsh CJ. Use of antithrombotic agents during pregnancy. Chest 1992; 102 (Supl): 385-390.
55. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-656.
56. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331: 1.601-1.606.
57. Spannagel U, Kujath P. Low molecular weight heparin for the prevention of thromboembolism in out patients inmobilized by plaster cast. Semin Thromb Haemost 1993; 19 (Supl 1): 131-141.
58. Turpie AGG, Gent M, Côte R, Levine MN, Ginsberg JS, Powers PJ et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep venous thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992; 117: 353-357.
59. Green D, Lee MY, Lim AC, Chmiel JS, Vetter M, Pang T et al. Prevention of thromboembolism after spinal word injury using low-molecular-weight heparin. Ann Intern Med 1990; 113: 571-574.
60. Kakkar AK, Williamson RCN. Thromboprophylaxis in malignant disease. Br J Surg 1995; 82: 742-745